XML 77 R31.htm IDEA: XBRL DOCUMENT
v3.20.1

Revenue (Tables) | 12 Months Ended
--- | ---
Apr. 24, 2020
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The table below illustrates net sales by segment and division for fiscal years 2020, 2019, and 2018:
| Net Sales by Fiscal Year(1) |  |  |  |
(in millions) | 2020 |  | 2019 |  | 2018
Cardiac Rhythm & Heart Failure | $ | 5,141 |  |  | $ | 5,849 |  |  | $ | 5,947 |
Coronary & Structural Heart | 3,541 |  |  | 3,730 |  |  | 3,562 |
Aortic, Peripheral & Venous | 1,786 |  |  | 1,926 |  |  | 1,845 |
Cardiac and Vascular Group | 10,468 |  |  | 11,505 |  |  | 11,354 |
Surgical Innovations | 5,513 |  |  | 5,753 |  |  | 5,537 |
Respiratory, Gastrointestinal, & Renal | 2,839 |  |  | 2,725 |  |  | 3,179 |
Minimally Invasive Therapies Group | 8,352 |  |  | 8,478 |  |  | 8,716 |
Brain Therapies | 2,922 |  |  | 2,938 |  |  | 2,354 |
Spine | 2,503 |  |  | 2,654 |  |  | 2,668 |
Specialty Therapies | 1,193 |  |  | 1,307 |  |  | 1,556 |
Pain Therapies | 1,107 |  |  | 1,284 |  |  | 1,165 |
Restorative Therapies Group | 7,725 |  |  | 8,183 |  |  | 7,743 |
Diabetes Group | 2,368 |  |  | 2,391 |  |  | 2,140 |
Total | $ | 28,913 |  |  | $ | 30,557 |  |  | $ | 29,953 |
(1)The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. The table below includes net sales by market geography and segment for fiscal years 2020, 2019, and 2018:
| Net Sales by Fiscal Year(4) |  |  |  |
(in millions) | 2020 |  | 2019 |  | 2018
U.S.(1) | $ | 5,062 |  |  | $ | 5,750 |  |  | $ | 5,681 |
Non-U.S. Developed Markets(2) | 3,519 |  | 3,767 |  | 3,790
Emerging Markets(3) | 1,887 |  | 1,988 |  | 1,883
Cardiac and Vascular Group | 10,468 |  | 11,505 |  | 11,354
U.S.(1) | 3,532 |  | 3,630 |  | 3,804
Non-U.S. Developed Markets(2) | 3,169 |  | 3,250 |  | 3,378
Emerging Markets(3) | 1,651 |  | 1,598 |  | 1,534
Minimally Invasive Therapies Group | 8,352 |  | 8,478 |  | 8,716
U.S.(1) | 5,122 |  | 5,478 |  | 5,164
Non-U.S. Developed Markets(2) | 1,659 |  | 1,759 |  | 1,720
Emerging Markets(3) | 945 |  | 946 |  | 859
Restorative Therapies Group | 7,725 |  | 8,183 |  | 7,743
U.S.(1) | 1,204 |  | 1,336 |  | 1,226
Non-U.S. Developed Markets(2) | 940 |  | 855 |  | 739
Emerging Markets(3) | 224 |  | 200 |  | 175
Diabetes Group | 2,368 |  | 2,391 |  | 2,140
U.S.(1) | 14,919 |  | 16,194 |  | 15,875
Non-U.S. Developed Markets(2) | 9,287 |  | 9,631 |  | 9,627
Emerging Markets(3) | 4,707 |  | 4,732 |  | 4,451
Total | $ | 28,913 |  |  | $ | 30,557 |  |  | $ | 29,953 |
(1)U.S. includes the United States and U.S. territories. (2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe. (3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above. (4)The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration